Bush Tia L's Form 4 filing
Centessa Pharmaceuticals plc (CNTA) · filed Nov 18, 2025
- Accession no.
- 0001470831-25-000343
- Filed
- Nov 18, 2025
- Trade date
- Nov 17, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.12M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bush Tia LCIK 0001863418 | Officer (Chief Technology & Quality Ofc) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Ordinary Shares | MOption exerciseAcquired | +40,000 | $9.42 | +$376,800 | 161,503 | Direct | |
| Nov 17, 2025 | Ordinary Shares | SSaleDisposed | −40,000 | $28.00 | −$1,120,000 | 121,503 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Ordinary Shares | MOption exerciseDisposed | −40,000 | $0.00 | $0 | 360,338 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.